CLSK
CleanSpark, Inc.
There isn't enough reported data to score CLSK yet.
MU
Micron Technology, Inc.
MU's fundamentals are strong and it looks cheap: trading at 11x earnings, about half its usual 22x. Analysts expect strong earnings growth.
CLSK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Weak |
CLSK's revenue is currently healthy, but its profitability and balance sheet are weak. There isn't enough data to rate its cash flow.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
CLSK PE Valuation
CLSK has no meaningful PE right now: it lost money over the past year.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU's PE is in its cheap range at 11x. If earnings grow as analysts expect, today's price would be 4.6x next year's earnings.
CLSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CLSK's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
MU has the edge over CLSK on the outlook, with more favorable earnings and revenue expectations.
CLSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.80 | -614% |
| Q1 2026 | -$2.09 | -$1.02 |
| Q4 2025 | -$1.06 | -$1.06 |
| Q3 2025 | $1.12 | +$1.81 |
| Q2 2023 | -$1.77 | -$1.25 |
| Q1 2023 | -$2.36 | -$2.06 |
| Q4 2022 | -$2.13 | -$2.05 |
| Q3 2022 | -$1.35 | -$0.60 |
CLSK has swung to a loss: it lost $3.80 per share over the past year, after a profit the year before.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU has the edge over CLSK on earnings quality, reporting a profit while its opponent remains loss making.
CLSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $89.3M | +70% |
| Q2 2024 | $104.1M | +129% |
| Q1 2024 | $111.8M | +163% |
| Q4 2023 | $73.8M | +165% |
| Q3 2023 | $52.5M | +101% |
| Q2 2023 | $45.5M | +47% |
| Q1 2023 | $42.5M | +2.2% |
| Q4 2022 | $27.8M | -33% |
MU has the stronger quarterly revenue trend. Revenue is up 70% for CLSK versus up 379% for MU.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -73% | +58 points |
| Q2 2024 | -239% | -205 points |
| Q1 2024 | 123% | +164 points |
| Q4 2023 | 39% | +143 points |
| Q3 2023 | -132% | +24 points |
| Q2 2023 | -34% | +14 points |
| Q1 2023 | -41% | -49 points |
| Q4 2022 | -104% | -115 points |
CLSK's operating margin was −73% last quarter, up 58 points from the same quarter a year ago.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU's revenue has grown year over year for 12 quarters in a row: $54.2B last quarter, up 379% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU's operating margin was 81% last quarter, up 48 points from the same quarter a year ago, near the top of its range since 2019.
CLSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$118.4M | -$8.5M |
| Q1 2026 | -$173.4M | -$61.1M |
| Q4 2025 | -$198.1M | -$78.6M |
| Q2 2025 | -$109.9M | -$31.5M |
| Q1 2025 | -$112.3M | -$53.9M |
| Q4 2024 | -$119.5M | -$51.9M |
| Q3 2024 | -$95.5M | -$32.7M |
| Q2 2024 | -$78.3M | -$59.1M |
MU has the stronger cash trend. Its trailing FCF is up 3,213% versus its history, compared with CLSK at down 283%.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU generated $59B in free cash flow over the past year, more than ten times what it generated the year before.
CLSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -11M shares |
| 1 year | -21% | -68.8M shares |
| 3 years | +287% | +190M shares |
| 5 years | +4901% | +252M shares |
CLSK has the edge over MU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $460M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $145M |
CLSK spent $460M buying back its own shares over the past year.
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has 1.1B diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
CLSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 150.4x | High |
| Q4 2025 | 7.4x | High |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | -20.5x | Net Cash |
| Q2 2024 | -14.8x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
CLSK's net debt is more than 20 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has more cash than debt.
CLSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CLSK's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
CLSK PE vs Technology Sector
| Metric | CLSK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CLSK has no meaningful PE right now: it lost money over the past year.
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU is trading at 11x earnings, a 61% discount to the Technology sector's median of 28x.
CLSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.27 | 26% below |
| 20 week MA | $11.5 | 40% below |
| 50 week MA | $12.0 | 43% below |
| 100 week MA | $11.5 | 41% below |
| 200 week MA | $10.5 | 35% below |
CLSK is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has the edge over CLSK on trend strength, trading above more of its moving averages.
CLSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $24.9 | +54% |
| 2021 | $24.9 | $11.9 | -52% |
| 2022 | $11.9 | $1.97 | -83% |
| 2023 | $1.97 | $11.0 | +460% |
| 2024 | $11.0 | $9.78 | -11% |
| 2025 | $9.78 | $10.9 | +12% |
| 2026 YTD | $10.9 | $6.84 | -37% |
CLSK's yearly returns have swung widely, from +460% in 2023 to −83% in 2022. It's down 37% so far in 2026.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over CLSK on returns for 2026, with the stronger performance.